Kumar Digvijay
Overview
Explore the profile of Kumar Digvijay including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
320
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Da Luz L, Ankawi G, Digvijay K, Rosner M, Ronco C
Blood Purif
. 2020 Jul;
50(1):42-49.
PMID: 32683368
Technique failure (TF) is a well-recognized challenge encountered in patients undergoing peritoneal dialysis (PD). Identification of patients at risk for this complication is of utmost importance. Early detection of patients...
2.
Sun J, Zhang J, Tian J, Virzi G, Digvijay K, Cueto L, et al.
J Am Soc Nephrol
. 2019 May;
30(7):1151-1161.
PMID: 31076465
AKI is a common clinical condition associated with the risk of developing CKD and ESKD. Sepsis is the leading cause of AKI in the intensive care unit (ICU) and accounts...
3.
Xie Y, Ankawi G, Yang B, Garzotto F, Passannante A, Breglia A, et al.
Kidney Int
. 2019 Apr;
95(6):1486-1493.
PMID: 30982674
The G1 cell cycle inhibitors tissue inhibitor metalloproteinase-2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7) have been identified as novel biomarkers for the prediction of moderate to severe acute...
4.
Digvijay K, Neri M, Fan W, Ricci Z, Ronco C
Blood Purif
. 2018 Oct;
47(1-3):113-119.
PMID: 30269144
Introduction: Definition, prevention, and management of acute kidney injury (AKI) and the optimal prescription and delivery of renal replacement therapy (RRT) are currently matters of ongoing discussion. Due to the...
5.
Fan W, Ankawi G, Zhang J, Digvijay K, Giavarina D, Yin Y, et al.
Clin Chem Lab Med
. 2018 Sep;
57(5):567-576.
PMID: 30179848
NephroCheck® is the commercial name of a combined product of two urinary biomarkers, tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7), expressed as [TIMP-2]·[IGFBP7], used to...
6.
Zhang J, Tian J, Sun H, Digvijay K, Neri M, Bhargava V, et al.
Blood Purif
. 2018 Sep;
46(4):326-331.
PMID: 30173223
Sepsis is the leading cause of acute kidney injury (AKI) in the intensive care unit. As the most common treatment of septic AKI, it is believed that continuous renal replacement...
7.
Zhang J, Ankawi G, Sun J, Digvijay K, Yin Y, Rosner M, et al.
Crit Care
. 2018 May;
22(1):117.
PMID: 29724256
Sepsis is the leading cause of acute kidney injury (AKI) in the intensive care unit (ICU). Septic AKI is a complex and multifactorial process that is incompletely understood. During sepsis,...
8.
Mohania D, Chandel S, Kumar P, Verma V, Digvijay K, Tripathi D, et al.
Adv Exp Med Biol
. 2017 Nov;
996:71-87.
PMID: 29124692
UV-radiations are the invisible part of light spectra having a wavelength between visible rays and X-rays. Based on wavelength, UV rays are subdivided into UV-A (320-400 nm), UV-B (280-320 nm)...